Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Removes Ciphergen from Biotech Index

NEW YORK, Nov. 14 (GenomeWeb News) - Ciphergen Biosystems has been removed from the Nasdaq Biotechnology Index as part of an semi-annual update, the exchange said today.

 

The index, which can be seen here, currently lists 152 companies. As part of the re-ranking, seven will be removed and 17 added. The changes take effect at the start of trading on Monday, Nov. 21.

 

The exchange updates NBI semi-annually, in May and November. Securities must meet the maintenance criteria of $100 million in market capitalization and 50,000 shares average daily trading volume to remain in the index. Securities missing the criteria for two consecutive rankings are removed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.